EP Wealth Advisors LLC Purchases 16,149 Shares of Boston Scientific Corporation $BSX

Key Points

• EP Wealth Advisors LLC increased its stake in Boston Scientific Corporation (BSX) by 83.0% in the first quarter, now holding shares valued at $3.59 million.
• Major institutional investors, including GAMMA Investing LLC and Vanguard Group Inc., have significantly increased their holdings, with institutional ownership standing at 89.07% of the company’s stock.
• Boston Scientific reported a strong quarterly performance with $5.06 billion in revenue, and earnings per share of $0.75, exceeding analysts' expectations.

EP Wealth Advisors LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 83.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,603 shares of the medical equipment provider's stock after purchasing an additional 16,149 shares during the period. EP Wealth Advisors LLC's holdings in Boston Scientific were worth $3,592,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. HM Payson & Co. increased its position in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after purchasing an additional 98 shares in the last quarter. Park Square Financial Group LLC grew its position in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 103 shares during the period. HHM Wealth Advisors LLC lifted its stake in shares of Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after acquiring an additional 103 shares during the period. Forum Financial Management LP raised its position in Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after buying an additional 112 shares during the last quarter. Finally, Paladin Wealth LLC increased its holdings in shares of Boston Scientific by 1.6% during the 1st quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock worth $722,000 after acquiring an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $18,397,457. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.9%

BSX traded up $0.92 during mid-day trading on Monday, reaching $108.14. 7,418,403 shares of the stock were exchanged, compared to its average volume of 7,455,042. The company has a 50 day moving average price of $104.77 and a two-hundred day moving average price of $102.15. The stock has a market capitalization of $160.23 billion, a PE ratio of 64.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 earnings per share. The firm's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. UBS Group boosted their price target on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Citigroup reissued a "buy" rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.